Inotuzumab ozogamicin

BNF:
not listed
Status:
Red
Decision Date:
October 2018
 

Comments

RED1,2,3,8: NICE TA541: for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. (Decision date - October 2018)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app